Intermittent Claudication - Pipeline Review, H2 2016

  • ID: 3804668
  • Report
  • 51 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • ID Pharma Co., Ltd.
  • Kowa Company, Ltd.
  • Nuo Therapeutics, Inc.
  • MORE
Intermittent Claudication - Pipeline Review, H2 2016

Summary

‘Intermittent Claudication - Pipeline Review, H2 2016’, provides an overview of the Intermittent Claudication pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Intermittent Claudication, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Intermittent Claudication and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Intermittent Claudication
- The report reviews pipeline therapeutics for Intermittent Claudication by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Intermittent Claudication therapeutics and enlists all their major and minor projects
- The report assesses Intermittent Claudication therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Intermittent Claudication

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Intermittent Claudication
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Intermittent Claudication pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • ID Pharma Co., Ltd.
  • Kowa Company, Ltd.
  • Nuo Therapeutics, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Intermittent Claudication Overview

Therapeutics Development

Pipeline Products for Intermittent Claudication - Overview

Intermittent Claudication - Therapeutics under Development by Companies

Intermittent Claudication - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Intermittent Claudication - Products under Development by Companies

Intermittent Claudication - Companies Involved in Therapeutics Development

ID Pharma Co., Ltd.

Kowa Company, Ltd.

Nuo Therapeutics, Inc.

Pluristem Therapeutics Inc.

Intermittent Claudication - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

ALD-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DVC-10101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

K-134 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LT-0101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLX-PAD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Intermittent Claudication - Dormant Projects

Intermittent Claudication - Discontinued Products

Intermittent Claudication - Product Development Milestones

Featured News & Press Releases

May 16, 2016: Pluristem Completes Enrollment of 150 Patients in Phase II Intermittent Claudication Trial

Aug 17, 2015: Pluristem Granted U.S. Patent for Production Methods and Use of Placental Cell Therapy in a Range of Indications

Nov 13, 2013: Pluristem Receives Regulatory Approval to Extend Its Phase II Study of PLX-PAD Cells in the Treatment of Intermittent Claudication to South Korea

Oct 02, 2013: Pluristem Receives Israeli Ministry of Health Approval to Expand Its Phase II Clinical Trial in Intermittent Claudication to Israel

Sep 16, 2013: FDA Lifts Clinical Hold of Pluristem's Phase II Intermittent Claudication Study

Jul 08, 2013: Pluristem's South Korean Partner Files IND With Korean FDA for PLX Cells

Jun 04, 2013: Pluristem To Receive Clinical-hold Notice From FDA For US Phase II Intermittent Claudication Study

Jan 15, 2013: Pluristem Receives Approval To Expand Phase II Clinical Trial In Intermittent Claudication To Germany

Aug 23, 2012: Pluristem Commences Phase II Clinical Trial For Intermittent Claudication Using PLX Cells

Aug 13, 2012: Pluristem Moves Intermittent Claudication Indication Forward in Germany Through Collaboration With Cato Research

Jul 18, 2012: Pluristem Partners With CPC Clinical Research For Peripheral Artery Disease Study

Apr 17, 2012: Pluristem Receives FDA Clearance For Phase II Clinical Trial In Intermittent Claudication

Jan 11, 2012: Kowa Initiates Japan Phase IIb Clinical Trials Of Anti-Platelet Agent K-134

Dec 02, 2011: Kowa Releases Japan Phase IIb Clinical Trials Data Of Anti-Platelet Agent, K-134

Nov 10, 2011: Kowa Announces Efficacy And Safety Of K-134 For Treatment Of Intermittent Claudication In AHA 2011

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 51List of Tables

Number of Products under Development for Intermittent Claudication, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Intermittent Claudication - Pipeline by ID Pharma Co., Ltd., H2 2016

Intermittent Claudication - Pipeline by Kowa Company, Ltd., H2 2016

Intermittent Claudication - Pipeline by Nuo Therapeutics, Inc., H2 2016

Intermittent Claudication - Pipeline by Pluristem Therapeutics Inc., H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Intermittent Claudication - Dormant Projects, H2 2016

Intermittent Claudication - Discontinued Products, H2 2016 42List of Figures

Number of Products under Development for Intermittent Claudication, H2 2016

Number of Products under Development by Companies, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • ID Pharma Co., Ltd.
  • Kowa Company, Ltd.
  • Nuo Therapeutics, Inc.
  • MORE
According to our recently published report 'Intermittent Claudication – Pipeline Review, H2 2016'; Intermittent Claudication pipeline therapeutics constitutes close to 5 molecules. which approximately 5 molecules are developed by Companies.

Furthermore, the publisher says; Intermittent Claudication Intermittent claudication is caused by narrowing or blockage in the main artery that takes blood to leg. Symptoms include burning or tingling sensation, decreased or absent pulse in the lower limb, pale or bluish skin, poor hair growth on the legs and sores or wounds on the lower limb that heal slowly, poorly. Risk factors include smoking, high cholesterol, high blood pressure, obesity, diabetes, age and family history.

The report 'Intermittent Claudication – Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Intermittent Claudication, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews of key players involved in therapeutic development for Intermittent Claudication and features dormant and discontinued projects. Currently, The molecules developed by Companies in Phase II and Discovery stages are 4 and 1 respectively.
Note: Product cover images may vary from those shown
5 of 6
ID Pharma Co., Ltd.
Kowa Company, Ltd.
Nuo Therapeutics, Inc.
Pluristem Therapeutics Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll